Advaxis (NASDAQ:ADXS)

CAPS Rating: 1 out of 5

Caps

How do you think ADXS will perform against the market?

Add Stock to CAPS Watchlist

All Players

49 Outperform
19 Underperform
 

All-Star Players

9 Outperform
12 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top ADXS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

GorGecko99 (21.75)
Submitted May 22, 2016

Leader in immunotherapy research. Great long-term potential.

zzlangerhans (99.58)
Submitted October 09, 2015

Advaxis has pulled off the surprising feat of not only recovering all the ground lost on the after hours plunge on Tuesday after announcement of the ADXS-HPV clinical hold, but they've actually gained ground from before the hold was announced. And… More

ADXS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ADXS.

Recs

0
Member Avatar Bigsef77 (70.31) Submitted: 3/13/2018 10:04:36 AM : Underperform Start Price: $23.99 ADXS Score: +123.93

Advaxis Inc. ADXS, -14.93% shares sank in the extended session Monday after the biotech company's cancer-drug study was placed on hold following the death of a patient in the study. Advaxis shares fell 24% after hours, following an initial halting. Shares finished up 0.5% at $2.21 in regular trading Monday. The clinical hold affects the company's clinical trial for the combination of the drugs Imfinzi and axalimogene filolisbac for the treatment of human papillomavirus-associated cervical cancer and HPV-associated head and neck cancer. "Enrollment and further dosing are on hold in this trial while the company, its partner and the [Food and Drug Administration] work closely with the site investigator to review this event in detail and to resolve this clinical hold," the company said in a statement.

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 5/25/2016 8:45:23 PM : Outperform Start Price: $8.74 ADXS Score: -112.75

Leader in cancer immunotherapy. Many different potential successful drugs in the FDA pipeline.

Recs

1
Member Avatar GorGecko99 (21.75) Submitted: 5/22/2016 11:58:23 AM : Outperform Start Price: $7.92 ADXS Score: -113.26

Leader in immunotherapy research. Great long-term potential.

Leaderboard

Find the members with the highest scoring picks in ADXS.

Score Leader

carsondyle

carsondyle (76.09) Score: +355.27

Should return to previous high around 30 again, back in for the ride.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
km00nster < 20 6/9/2015 Underperform 5Y $26.75 -93.61% +32.95% +126.56 0 Comment
vaipalolo 85.63 6/15/2015 Underperform 1Y $23.00 -92.57% +32.83% +125.39 0 Comment
Bigsef77 70.31 4/24/2015 2/22/2018 Underperform 1Y $23.99 -92.87% +31.06% +123.93 1 Comment
Iwannabeadored 38.87 4/20/2015 Underperform 5Y $18.65 -90.83% +32.56% +123.39 0 Comment
Clint35 63.71 5/1/2015 Underperform NS $17.12 -90.01% +32.34% +122.36 0 Comment
Zencyclone 29.96 3/16/2015 Underperform 5Y $14.05 -87.83% +33.40% +121.23 0 Comment
patatepoil6 99.81 3/4/2016 Underperform 5Y $8.82 -80.61% +38.10% +118.71 0 Comment
ziggystraw 98.98 1/9/2015 Underperform 5Y $10.14 -83.14% +35.51% +118.65 0 Comment
NobleOrSomeBull 99.39 2/9/2016 Underperform 5Y $5.48 -68.80% +49.73% +118.52 0 Comment
OptimistPrime2 95.67 3/5/2015 Underperform 5Y $10.85 -84.24% +31.75% +115.99 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ADXS.

Featured Broker Partners


Advertisement